Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 20, 2017
Pharmacy Choice - News - Pharmaceutical Development - January 20, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

1/20/17 - "Process for Purification and Isolation of Estrogens" in Patent Application Approval Process (USPTO 20160375378)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Akula, Chandrashaker; Lomans, John; Tummidi, Madhukiran; Tatake, Prashant Anil, filed on September 12, 2016, was made available online on January 5, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent appl
1/20/17 - Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B [Sudan Tribune]
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that the European Medicines Agency Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeonas gene therapy program ABO-101 for children impacted by Sanfilippo...
1/20/17 - Adamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA [Tehran Times (Iran)]
-Adamis Pharmaceuticals Corporation today announced that the U.S. Food and Drug Administration has accepted for review the Companys New Drug Application for its Epinephrine Pre-filled Syringe product candidate for the emergency treatment of anaphylaxis. Filed on December 15, 2016, the resubmission was intended to address the issues raised by the FD
1/20/17 - Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the results of additional data analyses related to cognitive function from its 12- week, randomized, double-blind, placebo-controlled Phase IIb clinical trial of MIN-101 as...
1/20/17 - ADMP Waiting To See If 3rd Time Is Charm, FDA Nod For SGYP, Be All Ears For OTIC
SAINT HELIER- AbbVie's blockbuster blood cancer drug Imbruvica has been approved by the FDA for yet another indication- this time, for the treatment of patients with relapsed/refractory marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy. Adamis Pharmaceuticals Corp.' s resubmitted New Dr
1/20/17 - Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
By a News Reporter-Staff News Editor at Drug Week Gilead Sciences, Inc. announced that Alessandro Riva, MD, will join the company as Senior Vice President, Hematology and Oncology Therapeutic Area Head. Dr. Riva joins Gilead from Novartis Oncology, where he served as Head, Global Oncology Development. Prior to joining Novartis, Dr. Riva co-founde
1/20/17 - Amorsa Therapeutics Announces Strategic Collaboration Facilitated by Johnson & Johnson Innovation to Develop New Therapy for Treatment-Resistant...
By a News Reporter-Staff News Editor at Drug Week- Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders has announced a research, option and license agreement with Janssen Pharmaceuticals, Inc. to develop and commercialize a novel small molecule drug candidate
1/20/17 - Amplitude Surgical Announces That is Has Been Granted Approval to Market Its Anatomic Total Knee Prosthesis in the United States
Amplitude Surgical, a leading French player on the global surgical technology market for lower-limb orthopedics, today announces that it has received 510 regulatory clearance from the US Food and Drug Administration for its Anatomic implant, addressing degenerative knee disorders. Olivier Jallabert, Chairman and CEO of Amplitude Surgical, says:
1/20/17 - Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017 [FARS News Agency]
-Anavex Life Sciences Corp. and the International Rett Syndrome Foundation, doing business as Rettsyndrome.org today announced that Rettsyndrome.org has committed a financial grant of a minimum of $0.6 million to cover the majority of a planned U.S. multicenter Phase 2 clinical trial of ANAVEX 2-73 for the treatment of Rett syndrome.
1/20/17 - ARMO BioSciences Presents New Phase 1b Clinical Data for AM0010 in Advanced Pancreatic Cancer Patients at 2017 Gastrointestinal Cancers Symposium
ARMO BioSciences, Inc., a late-stage immuno-oncology company, presented new Phase 1 b clinical data on the Company's lead investigational immuno-oncology drug AM0010 at the 2017 Gastrointestinal Cancers Symposium, co-sponsored by the American Society of Clinical Oncology, taking place January 19-21, 2017 in San Francisco, CA.. "AM0010 induces th
1/20/17 - Aurobindo Receives FDA Approval for Ziprasidone HCl Capsules, 20 mg, 40 mg, 60 mg and 80 mg
Release date- 19012017- East Windsor, N.J.- Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Ziprasidone HCl Capsules, 20 mg, 40 mg, 60 mg and 80 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited's Ziprasidone HCl Capsules, 20 mg, 40 mg, 60 mg and 80 mg to be bioequivalent
1/20/17 - Avillion Strengthens Clinical and Regulatory Development Capabilities with the Appointment of Mark Weinberg as Chief Medical Officer
Dr Weinberg will be based in Chicago, USA. Dr Weinberg joins Avillion from Halloran Consulting Group, a consulting firm that provides strategic guidance and development expertise to life science companies, where he was Chief Medical Officer and Managing Director. Prior to Astellas, Dr Weinberg held various positions of increasing responsibility at.
1/20/17 - Bioreactors Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 20162024
The global bioreactor market is segmented on the basis of scale range, usage, end-user, control, materials, suppliers, and region.Sarasota, FL 01/20/2017 Global Bioreactors Market: Overview. Bioreactor or fermenter is requisite equipment required for bioprocessing. Bioreactors are specifically constructed systems or vessels that can support a
1/20/17 - Bird Rock Bio Receives Approval from ANVISA and CONEP to Initiate the First Phase 2 Study in Brazil of Gerilimzumab for Rheumatoid Arthritis
By a News Reporter-Staff News Editor at Drug Week Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced that it had received approval for the initiation of a 200 patient, Phase 2 rheumatoid arthritis clinical trial for gerilimzumab, a novel therapeutic antibody to the IL-6 cytokine, to be conducted solely in Brazil. Working c
1/20/17 - Catalyst Pharmaceuticals (NASDAQ: CPRX) Offering Novel Therapies for Rare Diseases
The main focus of Catalyst Pharmaceuticals, Inc. is the development of a treatment for Lambert-Eaton Myasthenic Syndrome a rare, autoimmune, neuromuscular disorder characterized by muscle weakness and autonomic dysfunction. Catalyst Pharmaceuticals is currently developing amifampridine phosphate specifically for the treatment of LEMS and...
1/20/17 - ChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Center in San Francisco
What: ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer, will visit the Nasdaq Entrepreneurial Center in San Francisco.
1/20/17 - Concert Pharmaceuticals Receives FDA Orphan Drug Designation for CTP-656 for the Treatment of Cystic Fibrosis
Concert Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted orphan drug designation for CTP-656, Concert s next generation CFTR potentiator being developed for the treatment of cystic fibrosis. In December 2016, Concert initiated a Phase 2 trial in the U.S. evaluating CTP-656 in cystic fibrosis patients w
1/20/17 - Custopharm Acquires Two ANDA Pharmaceutical Products From Perrigo
By a News Reporter-Staff News Editor at Drug Week HYPERLINK " http://www.custopharm.com/"\ nCustopharm, Inc., a U.S. leader in generic injectable products, announced that it has acquired two paragraph IV abbreviated new drug application products from HYPERLINK " http://www.perrigo.com/"\ nPerrigo Company plc. William Larkins, chief executive offi
1/20/17 - Daiichi Sankyo Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1402 in Patients with HER3-Positive Metastatic or Unresectable Breast Cancer
Release date- 19012017- Tokyo, Japan and Parsippany, N.J.- Daiichi Sankyo Company, Limited announced today the initiation of a three-part open-label phase 1/ 2 study in Japan with U3-1402, a novel HER3-targeting antibody drug conjugate, in patients with HER3-positive metastatic or unresectable breast cancer who are refractory or intolerant to stand
1/20/17 - DaVita Clinical Research and Prism Clinical Research Choose Verified Clinical Trials to Prevent Duplicate Enrollment in Clinical Trials [Sudan Tribune]
-DaVita Clinical Research, a specialty contract research organization with services spanning the full spectrum of drug and device development, and Prism Clinical Research, a leader in providing fully integrated clinical research services to pharma/device companies and clinicians, today announced Verified Clinical Trials has been selected by both...
1/20/17 - Eagle Pharmaceuticals' Pemetrexed NDA Submitted for Review
By a News Reporter-Staff News Editor at Drug Week Eagle Pharmaceuticals, Inc. announced that the 505 New Drug Application for its novel pemetrexed drug product has been submitted to the U.S. Food and Drug Administration. "We look forward to the FDA's decision on this NDA this year, and to continuing to work closely with the FDA through the revie
1/20/17 - FDA Accepts For Filing Supplemental New Drug Application sNDA For LILETTA levonorgestrel-releasing intrauterine system 52 mg
By a News Reporter-Staff News Editor at Drug Week- Allergan plc, a leading global pharmaceutical company, and Medicines360, a nonprofit global women's health pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application to potentially extend the duration of use
1/20/17 - FDA Grants Bayer Priority Review for Stivarga regorafenib for the Second-Line Systemic Treatment of Liver Cancer
By a News Reporter-Staff News Editor at Drug Week- Bayer announced that the U.S. Food and Drug Administration has granted priority review status for the supplemental New Drug Application for Stivarga tablets for the second-line systemic treatment of patients with hepatocellular carcinoma in the U.S. The FDA grants priority review to medicines
1/20/17 - Gainers & Losers Of The Day: CATB, MCUR, BIOC, SSH, ZYNE.
News: Catabasis' positive phase I data on Edasalonexent published in the Journal of Clinical Pharmacology. News: Leap Therapeutics Inc., with which Macrocure is merging, has reported promising biomarker data from a clinical study of DKN-01 in combination with Paclitaxel in esophageal cancer. Upon completion of the prospective merger, Macrocure will
1/20/17 - Gilead's MAA For Investigational Chronic Hepatitis C Therapy Validated By EMA
FOSTER CITY- Gilead Sciences, Inc. announced Friday that the European Medicines Agency has validated its Marketing Authorization Application or MAA for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir. SOF/VEL/VOX for the treatment of HCV will be reviewed by the EMA under the centralized licensing procedure for all...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415